Skip to main content
Clinical Trials/NCT06203067
NCT06203067
Active, not recruiting
Not Applicable

Type 1 Together: A Peer Mentorship Program to Bolster Use of Continuous Glucose Monitoring Systems Among Adolescents With Type 1 Diabetes

Nemours Children's Clinic1 site in 1 country37 target enrollmentApril 19, 2024

Overview

Phase
Not Applicable
Intervention
Type 1 Together
Conditions
Diabetes Mellitus, Type 1
Sponsor
Nemours Children's Clinic
Enrollment
37
Locations
1
Primary Endpoint
Intervention Acceptability
Status
Active, not recruiting
Last Updated
2 months ago

Overview

Brief Summary

The goal of this clinical trial is to evaluate a new way of helping adolescents with type 1 diabetes consistently use continuous glucose monitoring systems (CGM).

Families who participate will be assigned by chance to one of two groups. One group will continue to see their Endocrinology provider who can give recommendations on ways to use CGM.

The other group will be in our Type 1 Together program for 6 months. This will include:

  1. Monthly meetings with a community health worker with expertise in type 1 diabetes self-management,
  2. Access to CGM-specific educational resources hosted on a mobile app, and
  3. Meeting at least monthly with a mentor family who will provide mentorship on using CGM consistently.

The main questions the study aims to answer are:

  1. Do families like the Type 1 Together program?
  2. Do more families in the Type 1 Together program have better attitudes towards CGM, use CGM more consistently, and have lower HbA1c?
  3. Does the Type 1 Together program reduce racial and ethnic differences in attitudes towards CGM, consistent use of CGM, and HbA1c?
Registry
clinicaltrials.gov
Start Date
April 19, 2024
End Date
February 28, 2027
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Paul Enlow

Research Scientist

Nemours Children's Clinic

Eligibility Criteria

Inclusion Criteria

  • 12 to 17 years old
  • Diagnosed with type 1 diabetes for at least 6 months
  • Does not use CGM OR uses CGM \< 24 out of the past 30 days
  • Use CGM 24 to 30 of the past 30 days but most recent HbA1c was 9% or more
  • Able to read and write in English

Exclusion Criteria

  • Type 1 diabetes due to other medical condition (e.g., cystic fibrosis)
  • Intellectual disability
  • Severe psychiatric comorbidities

Arms & Interventions

Type 1 Together

In Type 1 Together, families will work with other families who have experience using CGM (Peer Mentors) to overcome common barriers to CGM use. Families in the Type 1 Together program will also have access to CGM-specific educational materials, a digital journal to facilitate patient-provider communication around issues with CGM, and social determinant of health screening and intervention with a diabetes community health worker.

Intervention: Type 1 Together

Standard of Care

Quarterly clinic visits with endocrinology provider.

Intervention: Standard of Care

Outcomes

Primary Outcomes

Intervention Acceptability

Time Frame: 6 months post-enrollment

How acceptable youth and caregivers find Type 1 Together. This information will be collected only from participants in the experimental arm using the Acceptability of Intervention Measure (scores range 1-5 with higher scores indicating greater acceptability).

Perceptions of continuous glucose monitoring systems

Time Frame: Baseline and 3, 6, 9, and 12 months post-enrollment.

Youth perceptions of the benefits and burdens of using continuous glucose monitoring systems will be assessed using the CGM Benefits and Burdens Scales (scores range 1-5 with higher scores indicating greater perceived benefits or burdens).

Continuous Glucose Monitoring System Use

Time Frame: Baseline and 3, 6, 9, and 12 months post-enrollment

The number of days a patient wore their continuous glucose monitoring system at least 12 hours over the past month.

HbA1c

Time Frame: Baseline and 3, 6, 9, and 12 months post-enrollment

HbA1c expressed as a percentage of glycosylated hemoglobin

Study Sites (1)

Loading locations...

Similar Trials